https://ojs.pharmadeals.net/index.php/pdr/issue/feedPharma Deals Review2024-03-02T04:29:19+00:00Taskin Ahmedtaskin.ahmed@uk.imshealth.comOpen Journal Systems<p>Pharma Deals holds the copyright on all materials published in <strong><em>Pharma Deals Review</em></strong> (Journal) unless specifically indicated, whether in print or electronic form, both as a compilation and as individual articles.</p><p>The following guidelines apply to individual users:</p><ol type="1"><li>Subscribing Users to the Journal may not share their username or password without the express written permission of the Publisher.</li><li>Users may not reproduce, post, re-distribute, sell, modify or create a derivative work of any content, without prior, express written permission of the Publisher. Permission is granted, however, to provide a limited amount of print or electronic content for purposes of regulatory approval, patent and/or trademark applications or other legal or regulatory purposes. For other permissions to reprint or copy Journal content, please contact a representative of the Publisher.</li><li>Systematic downloading by robots or other automatic processes is prohibited without explicit approval by the Publisher in writing.</li><li>Any use and/or copies of this Journal in whole or in part, must include the bibliographic citation, including author attribution, article title, DOI, the Journal name and its URL (web site address) and MUST include the copyright notice. Users may not remove, cover, overlay, obscure, block, or change any copyright notices, legends, or terms of use. </li></ol><p><strong><em>Pharma Deals Review</em></strong> publishes articles in full text with open access that are viewable to all visitors of the Journal website with or without a paid subscription. Use of open access articles is subject to the same limitations as other articles published in the Journal. The Publisher acknowledges the use of the open access logo, <span class="description en" lang="en" xml:lang="en"> licensed under the<em> </em><a class="extiw" title="w:Creative Commons" href="http://en.wikipedia.org/wiki/Creative_Commons"><em>Creative Commons</em></a><em> </em><a class="external text" title="http://creativecommons.org/licenses/by-sa/3.0/" rel="nofollow" href="http://creativecommons.org/licenses/by-sa/3.0/"><em>Attribution ShareAlike 3.0</em></a><em> </em>License</span></p>Pharma Deals Review (ISSN 1756-7874 online publication) is an electronic publication that augments the Pharma Deals v4 database to provide expert opinion and analyses. Unlike print publications, our expert editorial team publishes their articles immediately and continuously, ensuring you get vital deal information and analyses at the very earliest opportunity.<br /><br />http://www.pharmadeals.net/journal/pharmadealsreview/details/2857Merck KGaA Pays C4 Therapeutics US$16 M Upfront for Protein Degraders2024-03-18T03:04:20+00:00Lucy Haggertyenquiries@pharmaventures.comIn yet another move in the protein degradation space, Merck KGaA has signed a strategic discovery research collaboration with C4 Therapeutics focused on two targeted protein degraders against critical oncogenic proteins. C4 will receive US$16 M upfront as well as up to US$740 M in milestone payments to leverage its TORPEDO (Target Oriented Protein Degrader Optimiser) technology platform. The deal marks yet another collaboration focused on protein degradation by Merck, as it has already formed similar partnerships with companies such as Celeris Therapeutics, Amphista Therapeutics and Proxygen.2024-03-08T05:34:17+00:00http://www.pharmadeals.net/journal/pharmadealsreview/details/2855Gilead to Acquire CymaBay Therapeutics and its Liver Disease Drug for US$4.3 B2024-03-18T03:04:20+00:00Lucy Haggertyenquiries@pharmaventures.comIn a bid to bolster its liver portfolio, Gilead Sciences has agreed to acquire CymaBay Therapeutics for US$32.50 per share in cash, representing a total equity value of US$4.3 B. Through the deal, Gilead picks up access to the investigational asset, seladelpar, currently under US FDA review for the treatment of primary biliary cholangitis (PBC) with pruritus without cirrhosis or with compensated cirrhosis, with approval anticipated in the third quarter of 2024. If approved, the drug will join Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) as the only other treatment on the market for the chronic, autoimmune disease.2024-03-02T04:29:33+00:00